An educational overview of injectable NAD+: the coenzyme's identity and mechanism, what the single human study of infused NAD+ actually measured, what the two published randomized trials found, where NAD sits on the FDA's compounding list, and which widely repeated claims the record does not support. Educational use only, not medical advice.
Standard Access: This compound's three paid filesAll-Access Lifetime: all 55 guides + every printableEducational content only
NAD+ Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
NAD+ at a glance
What it is
Nicotinamide adenine dinucleotide, an endogenous coenzyme central to cellular energy metabolism (PubChem CID 5892; C21H27N7O14P2; 663.4 g/mol; CAS 53-84-9; INN nadide). A dinucleotide, not a peptide; supplied as a lyophilized powder.
Researched for
Cellular energy metabolism, mitochondrial function, DNA repair and sirtuin activity in preclinical and early clinical contexts.
Plasma half-life
No half-life for injected NAD+ has been published from a human study. The one human infusion study found plasma NAD+ and its metabolites unchanged for the first two hours (PMID 31572171).
Regulatory status
Not FDA-approved for any indication. On FDA's 503A bulk drug substances list, updated 14 May 2026, NAD sits in Category 1 (under evaluation) and the disodium salt trihydrate in Category 3 (nominated without adequate support). Not named on the WADA Prohibited List, but section S0 can still apply.
Educational reference. This page does not publish dose ranges or reconstitution arithmetic.
What it is / mechanism
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell that acts as an electron carrier in the mitochondrial electron transport chain, where it is central to ATP (energy) production. Beyond bioenergetics, NAD+ is a required substrate for two important enzyme families: sirtuins (SIRT1-7), which are involved in DNA repair, metabolic regulation and gene expression, and PARP enzymes, which participate in DNA damage response. Cellular NAD+ levels are reported to decline with age, which has driven research interest in NAD+ and its precursors (NMN, NR) as tools for studying cellular aging and metabolism. One identity point is worth stating plainly, because it changes how the rest of this page should be read: NAD+ is not a peptide. It is a dinucleotide — PubChem CID 5892, molecular formula C21H27N7O14P2, 663.4 g/mol, CAS 53-84-9 — and it carries an international nonproprietary name of its own, nadide. It sits in a peptide guide library because the research market supplies it the way it supplies peptides, as a lyophilized powder reconstituted with bacteriostatic water, not because it shares their chemistry. The familiar explanation that injection bypasses hepatic first-pass metabolism, and that a subcutaneous depot then releases the coenzyme gradually, is a mechanistic proposal rather than a measured finding: neither step has been demonstrated for NAD+ in a published human study. What has been measured in humans points somewhere less convenient, and is set out under half-life below.
Researched effects
In cell and animal models, restoring NAD+ availability is associated with markers of improved mitochondrial function, cellular energy metabolism and DNA repair activity. That body of work is large and reasonably consistent. The human evidence for the injectable form is a separate question, and it is much thinner. An earlier version of this page stated that a small randomized trial in adults over 45 reported improvements in self-reported energy and performance versus placebo. That sentence has been withdrawn, because the trial it describes did not test injectable NAD+. The study it matches is Yi et al., GeroScience 2023 (PMID 36482258): 80 healthy middle-aged adults randomized for 60 days to placebo or oral beta-nicotinamide mononucleotide (NMN) at 300, 600 or 900 mg once daily, with blood NAD concentration as the primary outcome and the six-minute walking test and the SF-36 general health survey among the secondary ones. NMN is an oral precursor that the cell converts into NAD+ — the same distinction this page draws elsewhere — so a result obtained with oral NMN cannot be reported as a result for injected NAD+. What is left, stated honestly: community reports from injectable protocols describe subjective changes in energy and physical performance, and the controlled human record for injectable NAD+ itself does not yet contain an efficacy result of that kind. Individual responses vary and none of this is a guaranteed outcome.
Evidence & regulatory status
Human evidence on what injected NAD+ does once it is in the body rests on one pilot study. Grant et al. (Frontiers in Aging Neuroscience, PMID 31572171) state in their own abstract that before their work “no data are currently available on the fate of directly infused NAD+ in a human cohort”. They infused NAD+ intravenously at 3 micromoles per minute over six hours and tracked NAD+ and its metabolites in plasma and urine. It is a pilot study and it is small, and it is nonetheless the primary human source for everything this page says about what injected NAD+ does once it is in the body.
The best-known efficacy result in this area belongs to a different molecule taken by a different route. Yi et al. (GeroScience 2023, PMID 36482258) randomized 80 healthy middle-aged adults to 60 days of placebo or oral NMN at 300, 600 or 900 mg daily; blood NAD concentration rose significantly in every NMN group at day 30 and day 60 against both placebo and baseline. NMN is an oral NAD+ precursor, not NAD+, and nothing in that trial was injected. Presented as evidence for injectable NAD+ it is a category error — one this guide previously made and has now corrected.
Two randomized trials have given injected NAD+ to people and published their results, both from hospitals in China, where NAD+ for injection is a registered medicine (approval number H41024721, as both papers state). This page previously said that the only randomized trial of intravenous NAD+ had published nothing; that was wrong, and it is withdrawn. In a heart-failure trial (Yu et al., Am J Cardiovasc Drugs 2026, PMID 40954388; ChiCTR2200059169), 180 adults with ischaemic cardiomyopathy received seven days of intravenous NAD+ or placebo on top of standard treatment: ejection fraction at one month averaged 45.4% against 42.4% (p = 0.024), while every clinical secondary endpoint, including six-month cardiac events and heart-failure admissions, fell short of significance. In a hearing-loss trial (Gao et al., Laryngoscope 2026, PMID 41035311; NCT05849519), 38 patients with sudden sensorineural hearing loss received standard treatment with or without daily intramuscular NAD+: hearing improved more with NAD+ (40.2 against 23.1 dB, p = 0.010), but the control group received no placebo injection. Neither trial measured energy or performance. A third, American trial has not reported. NCT06382688 (Nutraceuticals Research Institute) randomized 53 adults aged 40 and over, double-masked, across four arms: IV NAD+, IV nicotinamide riboside, oral nicotinamide riboside and a saline placebo. It completed in March 2024. Its registered primary outcome measures are blood pressure, heart rate, total NAD by dried blood spot, glucose, insulin and tolerable infusion rate — no energy or performance measure appears among them. No results are posted to the registry, no publication is indexed for it in PubMed, and the record's own status reads “unknown”.
The surrounding literature looks larger than it is until you read the interventions. A ClinicalTrials.gov search for nicotinamide adenine dinucleotide as an intervention returns 264 studies, while a search for “intravenous NAD+” returns 0 and “NAD+ infusion” returns 0: the great majority of those 264 study the oral precursors NR and NMN rather than NAD+ itself. A control search for semaglutide returns 755 studies on the same day, so the queries are working.
Regulatory, United States: the compounding position is unresolved rather than settled, and the two forms are treated differently. On FDA's list of bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026, “Nicotinamide Adenine Dinucleotide (NAD)” appears in Category 1 — substances under evaluation — alongside the reduced form NADH. “Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate” appears separately in Category 3, nominated without adequate support. NAD is not in Category 2, the short list of bulk substances FDA identifies as raising significant safety risks, which currently names six substances.
No US drug label describes an injectable NAD+ product. An openFDA drug-label search on the substance name nadide returns 44 labels: 43 over-the-counter, one prescription, and none by any intravenous route. Every record inspected is an oral or topical homeopathic combination product, and the single prescription record is a homeopathic oral formula in which nadide is one of eighteen listed substances. A control search for semaglutide returns 5 labels, so the absence is real rather than a failed query.
Regulatory, sport: NAD+ is not named on the WADA Prohibited List, and that is not the same as permitted. Section S0 covers substances with no current approval by any governmental regulatory health authority for human therapeutic use. This page previously said injectable NAD+ has no such approval anywhere; that was wrong and is withdrawn, because NAD+ for injection is a registered medicine in China. Whether S0 reaches NAD+ is therefore not something this page can settle, and “not listed” still cannot be read as “allowed”. Athletes should verify current status with their governing body, as the list is revised annually.
Research use: the information here is for educational and research-planning purposes only. NAD+ described in this context is a research chemical, not an approved drug or supplement, and is not intended to diagnose, treat, cure or prevent any disease.
Research timeline
Dated milestones taken from the primary records: the molecule's discovery, its first registered human study, the trials that shaped the evidence and the regulatory decisions. Each entry links to the record it comes from.
Arthur Harden and Hans von Euler-Chelpin share the Nobel Prize in Chemistry for their work on sugar fermentation, which includes co-zymase, the small coenzyme Harden separated from yeast juice and later identified as NAD. nobelprize.org · Chemistry 1929
A three-month open-label study of oral NADH, the reduced form sold as a supplement, in 25 patients with mild to moderate dementia finds no cognitive effect in the 19 who completed it. PMID 11459000
A pilot study follows NAD+ and its breakdown products in human plasma and urine during a six-hour intravenous infusion: plasma levels do not rise for the first two hours because the infused NAD+ is cleared as fast as it arrives. PMID 31572171
A single-centre randomized, placebo-controlled trial in 180 adults with heart failure from ischaemic cardiomyopathy gives a week of intravenous NAD+ on top of standard therapy: ejection fraction at one month improves more than with placebo, while the other outcomes show only trends. PMID 40954388
A randomized, double-blind trial in 38 patients with sudden sensorineural hearing loss reports greater hearing improvement and faster recovery when NAD+ is added to standard treatment. PMID 41035311
FDA's 503A list, as updated on this date, places NAD in Category 1, still under evaluation for pharmacy compounding, and a beta-NAD disodium salt in Category 3, nominated without adequate support. FDA · 503A categories, May 14, 2026
Records checked Oct 4, 2026
Claims at a glance
The claims most often made about this compound, each with the strongest kind of evidence we found for it. The grade says what was studied, not whether the claim is true; the line beside it says what that study showed.
Restores energy when injected or infusedNo study found. A PubMed search for trials of injected NAD+ on fatigue, energy or ageing returned two records: a heart-failure trial and a study of a drug that blocks NAD+. PubMed search, Oct 7, 2026
Slows ageingNo study found. The trial usually quoted gave a precursor, NMN, by mouth to 80 healthy adults; no trial has given people NAD+ itself and measured ageing. PMID 36482258
Improves heart functionHuman, randomised trial. In a placebo-controlled trial of 180 heart-failure patients, a week of infusions raised the heart's pumping fraction at one month; clinical events did not differ significantly. PMID 40954388
Helps hearing recover after sudden hearing lossHuman, randomised trial. In a randomised trial of 38 patients, adding NAD+ to standard treatment improved hearing more, but the comparison group received no placebo. PMID 41035311
Sharpens memory and focusNo study found. No trial has given people injected NAD+ for memory or thinking; an open-label study of oral NADH in dementia found no cognitive effect. PMID 11459000
The reasoning behind each grade, study by study, is in this guide's Benefit & Outcome Review.
Grades checked Oct 7, 2026
A printable reference sheet with the compound's key facts, storage guidance and a vial record comes with All-Access Lifetime.
Half-life & pharmacokinetics
No half-life for injected NAD+ has been published from a human study, and the figures repeated across the research market — “under an hour”, “around 45 minutes intravenously” — do not trace back to one. This page carried both until this revision and has withdrawn them. What the single human study measured is stranger, and more useful. Grant et al. (Frontiers in Aging Neuroscience, PMID 31572171) infused NAD+ intravenously at 3 micromoles per minute for six hours and sampled plasma and urine throughout. No change in plasma NAD+, or in its metabolites nicotinamide, methylnicotinamide, ADP-ribose or NMN, was detectable until after two hours. The authors' reading is that at that infusion rate NAD+ is rapidly and completely removed from the plasma for at least the first two hours. By six hours, urinary NAD+ and methylnicotinamide were both raised while urinary nicotinamide was not — a pattern they describe as consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity. That is a clearance and metabolite observation from one pilot study, not a pharmacokinetic constant. It also says nothing at all about the subcutaneous route, for which no human pharmacokinetic study of NAD+ exists.
Reported side effects & toxicology
Community- and clinic-reported side effects are usually mild and short-lived: injection-site discomfort or burning, notably with unbuffered subcutaneous formulations, transient flushing or warmth, brief nausea and mild headache. With intravenous administration, nausea, chest tightness and facial flushing are reported when an infusion is run too quickly. Infusion comfort is not a fringe complaint in this literature. One randomized trial of IV NAD+ (NCT06382688) registered “tolerable infusion rate” as one of its primary outcome measures, and ran a second stage specifically to look further at the tolerability and comfort of the intravenous route — the investigators treated the discomfort as the question rather than as a footnote. An earlier version of this page named a numeric threshold above which side effects were said to become more common. It has been removed: no published human study of this compound supports a threshold figure. Human safety data for injectable NAD+ remain limited.
Storage & handling
Lyophilized (powder) vials are reported to be stable stored refrigerated (2-8°C) and protected from light; many sources note the powder can tolerate short periods at room temperature during shipping.
Once reconstituted with bacteriostatic water, NAD+ should be kept refrigerated (2-8°C), protected from light, and used within a few weeks per common handling guidance.
NAD+ is reported to be sensitive to both light and repeated freeze-thaw, and its aqueous stability is pH-dependent, so handling guidance for this compound leans harder on protection from light and on avoiding repeated warming than it does for many peptides. Storage practice here is handling guidance, not a stability claim verified for any particular vial.
References
Primary sources for this page, each opened and checked: Grant et al., “A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+”, Frontiers in Aging Neuroscience (PMID 31572171); Yi et al., “The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults”, GeroScience 2023 (PMID 36482258); ClinicalTrials.gov record NCT06382688 and the registry counts quoted above; the FDA list of bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026; the openFDA drug-label database, substance name nadide; PubChem CID 5892; Yu et al., “Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial”, Am J Cardiovasc Drugs 2026 (PMID 40954388); Gao et al., “NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial”, Laryngoscope 2026 (PMID 41035311); and the WADA Prohibited List. Provided for educational purposes only and not as medical advice.
Evidence File
The NAD+ Evidence File: 104 Trial Records, Eleven That Gave NAD+ Itself, and Two New Trials From China
NAD+ looks like one of the most researched molecules in this library: PubMed indexes more than 32,000 records under its subject heading and 104 of them are typed as clinical trials. Read the 104 and most of them are about something else. Forty gave people a precursor such as nicotinamide riboside or NMN, thirteen gave NADH, the reduced form, usually by mouth, and thirty-six only measured NAD. Eleven gave NAD+ itself — eight of them between 1966 and 1971. The two that matter most were published in 2025 and 2026 by hospitals in China, where NAD+ for injection is a registered medicine, and neither is the trial the research market quotes. This file sorts the literature and says what each piece can support.
104 trial-typed records under the NAD heading; 11 gave people NAD+ itself
40 gave a precursor and 13 gave NADH — different molecules, often quoted as NAD+
2 published randomised trials of injected NAD+, both from China, both since 2025
1 human study of what happens to infused NAD+ in the blood
How large this literature is, and why almost none of it is about the injection
The two modern trials of injected NAD+, and what each one measured
1966 to 1971: NAD+ in schizophrenia and alcohol withdrawal
What happens to NAD+ once it is in the blood: one study
What has never been measured
5 more sections in the Evidence File for NAD+
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for NAD+ for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Sourcing File
The NAD+ Sourcing File: A Twin That Weighs Exactly the Same, a Salt That Is 13% Something Else, and a Molecule That Falls Apart in Alkali
NAD+ is not a peptide, and the usual peptide checks do not transfer cleanly. Its most important impurity, the alpha form, has exactly the same formula and mass as NAD+ and cannot be seen by a mass spectrum. Its reduced form, NADH, is two daltons heavier and is sold as a separate supplement. Its two breakdown products are the first thing a degraded vial shows. The powder may be the free acid or a sodium salt that is about 87% NAD+ by weight, and the FDA lists the two forms in different categories. And a licensed pharmaceutical version exists in China, which the research market's material is not. This file turns all of that into questions to put to a certificate of analysis.
663.4 g/mol — and an alpha twin at exactly the same mass that only chromatography can separate
2 daltons between NAD+ and NADH, the reduced form sold as a separate product
About 87% NAD+ by weight in the disodium salt trihydrate the FDA lists separately
2 breakdown products, nicotinamide and ADP-ribose, that a degraded vial shows first
What NAD+ is, and the neighbours a certificate must rule out
The impurity a mass check cannot see: alpha-NAD
Free acid or salt: what the powder actually contains
Stability: why storage matters more than it does for a peptide
What to ask a supplier, in the order to read it
5 more sections in the Sourcing File for NAD+
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for NAD+ for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Benefit & Outcome Review
The NAD+ Benefit & Outcome Review: One Heart Trial That Met Its Primary Endpoint, and No Trial of Anything It Is Bought For
NAD+ injections are bought for energy, for healthy ageing, for mental clarity, for recovery and, in clinics, for addiction and withdrawal. None of those has been tested in a published trial of injected NAD+. The randomised evidence that does exist concerns two hospital conditions: a 180-patient heart-failure trial in which NAD+ improved one measure of heart function at one month while every clinical secondary endpoint missed, and a 38-patient hearing-loss trial without a placebo injection. The famous energy result came from oral NMN. The addiction evidence is two small trials from 1966 and 1971. This review takes each claimed benefit in turn and separates what was measured from what is inferred.
0 trials of injected NAD+ measuring energy, fatigue, ageing, cognition or performance
38 hearing-loss patients, and no placebo injection in the control group
1966 and 1971 — the dates of the only controlled trials of NAD+ in alcohol withdrawal
Energy and healthy ageing: the claims that rest on a different molecule
The heart-failure trial: the strongest outcome result for NAD+ itself
The hearing-loss trial: a positive result with a design problem
Addiction, withdrawal and the mind: tested half a century ago, then left
What no benefit claim here can rest on
5 more sections in the Benefit & Outcome Review for NAD+
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for NAD+ for $14 — or every compound in the library, plus the printable reference sheets, for $99.
Quick answers about guide scope, access, and educational use context.
Is injectable NAD+ FDA-approved?
No, and its compounding status is unresolved rather than settled. Injectable NAD+ is not FDA-approved for any therapeutic indication, although NAD+ for injection is a registered medicine in China. On FDA's list of bulk drug substances nominated for compounding under section 503A, updated 14 May 2026, NAD appears in Category 1 — under evaluation — while the disodium salt trihydrate appears in Category 3, nominated without adequate support. It is handled as a research chemical in educational contexts. Nothing here is medical advice.
Is there an established subcutaneous NAD+ dose?
No. The subcutaneous amounts and schedules that circulate in community protocols come from no dose-finding study, and this page does not reproduce them. Nothing here is a personal dose recommendation.
Why does subcutaneous NAD+ sometimes burn or sting?
Subcutaneous NAD+ is frequently reported to cause a burning or stinging sensation, especially with unbuffered formulations. Slower injection, smaller split doses and buffered preparations are commonly described as ways to reduce this discomfort.
How is NAD+ different from NMN or NR?
NMN and NR are NAD+ precursors that cells convert into NAD+, and are typically taken orally. Injectable NAD+ delivers the coenzyme itself. The distinction is not academic when you read claims about this compound: the best-known randomized result in this area (PMID 36482258, 80 middle-aged adults, 60 days) used oral NMN, not injected NAD+, and its findings cannot be carried across. This is descriptive information, not a recommendation.
Is NAD+ prohibited in sport?
NAD+ is not named on the WADA Prohibited List. That is not the same as permitted. Section S0 covers substances with no current approval by any governmental regulatory health authority for human therapeutic use, and NAD+ for injection is a registered medicine in China, so how S0 applies is not settled by this page. Athletes should verify current status with their governing body rather than relying on absence from the list.
Is NAD+ a peptide?
No. NAD+ is a dinucleotide coenzyme — PubChem CID 5892, C21H27N7O14P2, 663.4 g/mol, CAS 53-84-9 — and it has an international nonproprietary name of its own, nadide. It appears in this peptide guide library because the research market supplies and reconstitutes it the same way peptides are supplied and reconstituted, not because it is chemically a peptide.
What happens to NAD+ after an intravenous infusion?
In the one published human study (Grant et al., PMID 31572171), an infusion at 3 micromoles per minute produced no detectable change in plasma NAD+ or its metabolites for the first two hours — the authors conclude it is rapidly and completely cleared from plasma over that period. By six hours, urinary NAD+ and methylnicotinamide were raised while urinary nicotinamide was not. That is a single pilot study, and it is the whole published human picture of how infused NAD+ is handled.
Has any randomized trial tested injectable NAD+?
Yes, two have published, both from China, and neither measured energy or performance. This page previously said none had reported; that was wrong and is withdrawn. A heart-failure trial in 180 adults (PMID 40954388) found a higher ejection fraction at one month after seven days of intravenous NAD+ than after placebo (45.4% against 42.4%), with no significant difference in any clinical secondary endpoint. A hearing-loss trial in 38 patients (PMID 41035311) found more hearing recovery with daily intramuscular NAD+, but its control group had no placebo injection. A third trial, NCT06382688, randomized 53 adults aged 40 and over to IV NAD+, IV nicotinamide riboside, oral nicotinamide riboside or saline placebo, double-masked, and completed in March 2024. Its primary outcomes were physiological and tolerability measures rather than energy or performance. No results are posted, no publication is indexed in PubMed, and the registry status reads “unknown”.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
A certificate of analysis (COA) is a laboratory’s report on one sample of one batch. The single most useful thing to know about it is that purity and identity are two separate results that fail in different ways. A high purity figure says the sample was mostly one substance; it does not say that substance was NAD+. Identity — normally a mass-spectrometry result matching the expected molecular weight — is what establishes what the material actually is, and a certificate reporting purity alone has not answered that question.
Two further limits are worth holding onto. Mass per vial is its own test: a vial can be 99% pure and still contain less material than the label claims. And sterility, endotoxin, heavy metals and residual solvent screening are separately commissioned tests, usually priced individually — so a “third-party tested” badge asserts none of them unless the certificate names them. Check that the batch or lot number on the document matches the vial in front of you; an unmatched certificate describes someone else’s material.
Medibact does not test, endorse or resell peptides, and publishes no rating of any laboratory. How to read a peptide certificate of analysis walks through the document section by section, and what each COA field establishes covers the field-by-field detail and the laboratories that publish their methods.
You’ll need bacteriostatic water
The diluent for reconstituting NAD+
Reconstitution is volume arithmetic — it assumes a lyophilized vial is dissolved in bacteriostatic water, which is sterile water preserved with 0.9% benzyl alcohol. The preservative is what allows a vial to be entered more than once; plain sterile water carries none and is single-entry by design. Medibact supplies USP-grade Bacteriostatic Water for Injection in a 30 mL multi-dose vial, made in the United States and shipped from the United States, for research use only. One 30 mL vial covers 30 reconstitutions at 1 mL each, 15 at 2 mL, or 10 at 3 mL — division only, not a dosing recommendation.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
